Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2b, multicenter, randomized, double-blind, parallel-group, placebo-controlled trial evaluating the efficacy and safety of dose regimens with oral tofacitinib in the treatment of subjects with moderate-to-severe chronic plaque psoriasis

Next Previous
Trial Profile

A phase 2b, multicenter, randomized, double-blind, parallel-group, placebo-controlled trial evaluating the efficacy and safety of dose regimens with oral tofacitinib in the treatment of subjects with moderate-to-severe chronic plaque psoriasis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Pfizer

Most Recent Events

  • 19 Nov 2020 Results of Bayesian network meta analysis assessing the relative efficacy and safety of tofacitinib administration (5 and 10 mg) twice daily in psoriasis patients published in the International Journal of Clinical Pharmacology and Therapeutics
  • 12 Mar 2016 Pooled analysis (n=3431) of 5 trials [NCT00678210, NCT01276639, NCT01309737, NCT01241591, NCT01186744] were presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
  • 02 Dec 2013 Results published in the Journal of Dermatological Treatment.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top